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The combination of immune checkpoint blockade with chemotherapy is currently under 
investigation as a promising strategy for the treatment of Triple Negative Breast Cancer 
(TNBC). Tumor-associated macrophages (TAM) are the most prominent component of 
breast cancer microenvironment because they influence tumor progression and the 
response to therapies. Here we show that macrophages acquire an immunosuppressive 
phenotype and increase the expression of programmed death ligand-1(PD-L1) when treated 
with reactive oxygen species (ROS) inducers such as the glutathione synthesis inhibitor 
BSO and paclitaxel. Mechanistically, these agents cause accumulation of ROS that in turn 
activate NF-kB signalling to promote PD-L1 transcription and the release of 
immunosuppressive chemokines. Systemic in vivo administration of paclitaxel promotes PD-
L1 accumulation on the surface of tumor-associated macrophages in a mouse model of 
TNBC, consistent with in vitro results. Combinatorial treatment with Paclitaxel and an anti-
mouse PD-L1 blocking antibody significantly improved the therapeutic efficacy of paclitaxel 
by reducing tumor burden and increasing the number of tumor-associated cytotoxic T cells. 
Our results provide a strong rationale for the use of anti-PD-L1 blockade in the treatment of 
TNBC patients. Furthermore, interrogation of chemotherapy-induced PD-L1 expression in 
TAM is warranted to define appropriate patient selection in the use of PD-L1 blockade.  
 
SIGNIFICANCE STATEMENT  
 
Immunotherapies targeting the programmed death-1 (PD-1) and its ligand PD-L1 have 
recently been combined with standard chemotherapy to potentiate the treatment of solid 
tumors, including Triple Negative Breast Cancer (TNBC). Reactive Oxygen Species (ROS) 
have been directly linked to the cytotoxic effects of chemotherapy. Here we report that ROS 
induced either by chemotherapy (paclitaxel) or antioxidant depletion induce PD-L1 
expression in macrophages. PD-L1-positive macrophages have immune-suppressive and 
angiogenic properties that interfere with the efficacy of paclitaxel in vivo. Indeed, PD-L1 
blockade reverts this effect and synergizes with paclitaxel to reduce tumor growth. Our work 
reveals a novel pathway that further supports the importance of combining taxane and PD-
L1 inhibitors as promising anti-cancer strategy in TNBC.  
 
\body 
INTRODUCTION 
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Triple-Negative Breast Cancer (TNBC) is an aggressive heterogeneous disease, which 
includes up to 20% of breast cancers (BC). Clinical treatment of this disease is particularly 
challenging and is currently limited to standard chemotherapy(1). Although TNBC are 
particularly sensitive to neoadjuvant chemotherapy with pathological complete response 
(pCR) rates of about 40%, these cancers maintain a high rate of relapse(2).  
TNBC was initially classified among the non-immunogenic “cold” tumors but recent studies 
have proved that the expression of immune-related genes and the presence of immune 
infiltrates in primary lesions are associated with a better clinical outcome(3, 4). TNBC is also 
characterized by genomic instability and high rates of genetic mutations, which implicate 
production of more neo-antigens and increased immunogenicity(5). These findings have 
encouraged the development of new combinatory strategies between chemotherapy and 
immune checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligand (PD-
L1)(6). In these settings, the use of PD-1/PD-L1 inhibitors could elicit or potentiate the 
antitumor response induced by chemotherapy(6). Indeed, ongoing clinical trials have shown 
that immune checkpoint blockade in combination with neoadjuvant chemotherapy correlates 
with an increased pathological complete response rates in TNBC patients(7). Although 
these clinical studies are reporting encouraging data on the efficacy of chemo-
immunotherapy, basic understanding of the interplay between chemotherapy and 
immunotherapy is limited.  
Among the most urgent needs, it is the characterization of biomarkers for a better 
stratification of TNBC patients in the response to these combinatorial strategies(8, 9). In 
some studies, PD-L1 expression have been evaluated by IHC in both cancer and stromal 
cells with the indication that PD-L1 expression among tumor-infiltrating immune cells may 
be a better robust predictor(7). Indeed, a recent work has found that analysis of PD-L1 levels 
on both cell types is necessary for predicting best response to atezolizumab (PD-L1 
inhibitor) in non-small cell lung cancer(10). Being a cell surface protein, it is conceivable that 
the expression of PD-L1 is regulated by external stresses in the tumor microenvironment 
(TME) and may represent a key node at the interface of extracellular and intracellular cancer 
signaling pathways.  
A well characterized mediator of chemotherapy-induced cytotoxicity is the accumulation of 
reactive oxygen species (ROS) in cancer and stromal cells(11, 12). In TNBC, tumor-
associated macrophages (TAM) support tumor progression and are potent regulator of 
therapeutic response in BC because they can suppress immune-based mechanism of 
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cytotoxic chemotherapy(13, 14). Based on these considerations, we speculated that 
chemotherapy-induced ROS could affect the expression of PD-L1 in macrophages and the 
immune properties of the TME. 
Here we report that ROS induced by the glutathione synthesis inhibitor, BSO positively 
regulates mRNA and protein surface expression of PD-L1 in human and mouse 
macrophages in vitro. These macrophages also produce immunosuppressive cytokines 
including IL-4, IL-10 and IL-17 and the angiogenic factor, Vascular Endothelial Growth 
Factor-A (VEGF-A). Interestingly, the chemotherapeutic drug and ROS inducer, paclitaxel, 
reproduced all BSO-mediated effects in macrophages. Furthermore, in mouse BRCA1/p53-
deleted mammary tumors, a model which resembles spontaneous TNBC, in vivo 
administration of paclitaxel induced PD-L1 expression in TAM as soon as 24h after 
treatment, leading to an immunosuppressive TME. Consequently, the in vivo combination 
of paclitaxel and an anti-PD-L1 blocking antibody reduced mammary tumor burden and 
reverted the immune-properties of TME. Our data show that ROS are novel regulators of 
PD-L1 expression, immune-suppressive and angiogenic features of macrophages. This 
study emphasises the importance of evaluating PD-L1 expression in TAM as predictive 
biomarker of chemo-immunotherapy response in TNBC patients. 
 
RESULTS 
 
ROS regulate PD-L1 expression and secretion of immunosuppressive cytokines in 
macrophages in vitro 
Recent work has shown that in tumor-bearing mice, tumor-associated macrophages (TAM) 
expressed much higher surface levels of PD-L1 than circulating monocytes, implying 
upregulation of PD-L1 by the tumor microenvironment(15). ROS generation and 
accumulation in TME have important implications in the initiation and progression of 
cancer(12). To elucidate if ROS could regulate the expression of PD-L1 in macrophages, 
we treated bone marrow-derived macrophages (BMDM) with BSO, which increases ROS 
by depleting reduced glutathione (GSH)(16). BSO positively induced PD-L1 mRNA levels in 
a ROS-dependent manner since its effect was reverted by co-treatment with the antioxidant 
and ROS quencer N-acetyl-cysteine (NAC) (Fig. 1A). This change coincided with modulation 
of intracellular ROS levels as shown by quantification of DCF-DA staining by flow cytometry 
(SI Appendix Fig. 1A). BSO-mediated effect on PD-L1 expression was greater when BMDM 
were first treated with IL-4 and M-CSF that polarize them toward alternatively-activated 
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macrophages with features similar to TAM (17) (SI Appendix Fig. S1B). The polarization of 
these BMDM was confirmed by the elevated expression of Arginase-1(17) (SI Appendix Fig. 
S1C). 
BSO also triggered the expression of the NRF2 antioxidant targets, Gclc, Gclm, Nqo1 and 
Hmox-1 as a response to the intracellular redox imbalance (Fig. 1B and SI Appendix, Fig. 
S1D). Data in mouse BMDM were validated in human monocyte-derived macrophages 
treated with BSO with or without NAC. Human macrophages increased PD-L1 mRNA levels 
as well as NRF2 target, NQO1, as a response to different ROS conditions (SI Appendix, Fig. 
S1E, F).  
Next, we investigated which population among BMDM was mainly affected by BSO in terms 
of PD-L1 protein surface expression. In BSO-treated mouse BMDM defined as CD11b and 
F4/80 double-positive cells (CD11b+F4/80+), PD-L1 expression was not affected by the 
presence of BSO (SI Appendix, Fig. S1G), but it completely coincided with a population 
characterized by high positivity of mannose receptor C type 1 (MRC1/CD206) and absence 
of expression of major histocompatibility complex class II (MHC-II) molecules (Fig. 1C and 
SI Appendix, Fig. S1H, I)  Of note, the CD206+MHC-II- macrophages are usually defined as 
alternatively-activated macrophages. (14, 18). By contrast, PD-L1 expression was almost 
unchanged in a population highly expressing MHC II (CD206-MHC II+)(Fig. 1D and SI 
Appendix, Fig. S1H,I). In human macrophages, PD-L1 surface staining increased in CD11b+ 
cells upon BSO and decreased when NAC was added to the culture (SI Appendix, Fig. S1J).   
PD-L1 expression has been previously associated with the immune-suppressive features of 
macrophages(19). Therefore, we analysed which cytokines were present in the media of 
BSO- and BSO+NAC-treated mouse BMDM by applying a mouse cytokine antibody array. 
We found that, compared to untreated cells, BSO stimulated production of Interleukin-10 
(IL-10), Interleukin-17 (IL-17), Interleukin-4 (IL-4), Interleukin-1 beta (IL-1b), Insulin-like 
growth factor-binding protein 3 (IGFBP-3) and chemokine (C-X-C motif) ligand 1 (CXCL1) 
(Fig. 1F). IL-10, IL-4, IGFBP-3 and CXCL1 are usually associated to an immune-suppressive 
phenotype of macrophages(20-23). IL-1b is a well-known pro-inflammatory cytokine that has 
been associated with breast cancer progression and ability to metastasize, especially to 
extravasate when induced by neutrophils with metalloproteases and other pro-inflammatory 
cytokines(24, 25). IL-17 is another inflammatory cytokines but it can enhance 
immunosuppression in several systems including macrophages(26). On the other hand, 
BSO-treated BMDM produced low levels of Interleukin-12 isoform (IL-12) p40/p70 
heterodimer and p40 monomer, as well as CD30L (TNFRSP8), CD40 and C-X-C motif 
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chemokine 10 (CXCL-10) (Fig. 1E). Overall, these data suggest that ROS drive a phenotypic 
change in macrophages characterized by reduced antigen presenting function and co-
stimulatory ability  (27-29). In the same cells, ROS also upregulated the production of VEGF-
A, indicative of angiogenic macrophages(30). Notably, NAC completely reverted the 
production of cytokines and VEGF-A induced by BSO, indicating a key role of ROS in these 
changes (Fig. 1E). 
ROS induction is a key component of the cytotoxic properties of chemotherapy(11). We 
compared three chemotherapeutic drugs for their ability to increase ROS in BMDM: the 
antimitotic agent paclitaxel, the poli ADP-ribosil polimerase (PARP) inhibitor olaparib and 
the platinum-based drug cisplatin (1). Compared to cisplatin and olaparib, paclitaxel induced 
the highest ROS levels in BMDM (SI Appendix, Fig. S2A). In contrast to cisplatin and 
olaparib, paclitaxel did not cause any DNA damage as measured by intracellular 
accumulation of phosphorylated H2AX (H2AX) (SI Appendix, Fig. S2B)(31). Paclitaxel-
induced ROS levels were not cytotoxic since BMDM had similar cellular viability in both 
untreated and treated conditions as measured by the sulforhodamine B (SRB) assay (SI 
Appendix, Fig. S2C). Given its ability of elevating ROS, paclitaxel triggered the expression 
of Pdl1 as compared to control cells that was reverted when ROS were scavenged by NAC 
(Fig. 1F and SI Appendix, Fig. S2D). Similarly to BSO, paclitaxel-mediated effect on PD-L1 
expression was augmented by polarization of BMDM toward alternatively-activated 
macrophages (SI Appendix, Fig. S2E). NRF2-regulated antioxidant genes, Gclc, Gclm and 
Hmox1 were also elevated in paclitaxel-treated BMDM (Fig. 1G and SI Appendix, Fig. S2F). 
Flow cytometry analysis also showed increased levels of PD-L1 specifically on the surface 
of CD206+ MHC-II- upon treatment with paclitaxel that was reduced by adding NAC (Fig. 1H 
and SI Appendix, Fig. S2G). On the contrary, CD206-MHC-II+ BMDM did not show any 
change (Fig. 1I and SI Appendix, Fig. S2G). Analysis of human macrophages recapitulated 
the elevation of both PD-L1 mRNA and surface protein after exposure to paclitaxel that was 
reverted by NAC (SI Appendix, Fig. S2H,I). The expression of the NRF2 antioxidant enzyme 
NQO1 was similarly regulated (SI Appendix, Fig. S2J). Then, we analysed the cytokine and 
growth factor production of BMDM treated with paclitaxel with or without NAC. Interestingly, 
media from paclitaxel-stimulated BMDM contained the same profile of cytokines observed 
after BSO treatment (Fig. 1J). In addition, we detected Fas ligand (Fasl) and C-X3-C Motif 
Chemokine Ligand (CX3CL1) (Fig. 1J). Fasl is a common mediator of apoptosis in T cells 
expressing the receptor Fas, whereas CX3CL1 functions as an adhesion molecule(32, 33). 
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The production of these cytokines was significantly reverted by co-treatment with NAC (Fig. 
1J).  
 
ROS-induced PD-L1 expression is mediated by the transcription factor NF-kB 
We noted that most of the cytokines induced by BSO and paclitaxel treatments have been 
previously characterized as transcriptional targets of the transcription factor NF-kB 
(https://www.bu.edu/nf-kb/gene-resources/target-genes/). Furthermore, it is known that 
activation of NF-kB can promote cell survival and prevent oxidative damage in response to 
ROS(34). Thus, we hypothesized that ROS might regulate PD-L1 expression through NF-
kB activation.  
NF-kB molecular forms are usually dimers and the dimer formation is necessary for DNA 
binding. The most abundant form of NF-kB dimer is p50/p65 heterodimer that mediates the 
canonical activation of the pathway(35). Upon phosphorylation on the two key residues, 
S276 and S536, p65 undergoes to a conformational change that triggers its transcriptional 
activity(35). In BSO- and paclitaxel-treated BMDM we found an increased frequency of cells 
positive for the phosphorylation of p65 at S536 residue by immunofluorescence staining 
(Fig. 2A and SI Appendix, Fig. S3A). The number of these cells was reduced by co-treatment 
with either the ROS quencher NAC or the nuclear factor kappa-B kinase-2 (IKK-2) inhibitor 
SC514 (Fig. 2A and SI Appendix, Fig. S3A)(36). Treatment with lipopolysaccharides (LPS) 
was used as positive control of p65 phosphorylation in BMDM (Fig. 2A)(37). These results 
were validated by measurement of P-p65 overall nuclear intensity in the same conditions 
(Fig. 2B and SI Appendix, Fig. S3B). We further verified the activation of NF-kB pathway by 
analysing the expression of the NF-kB target gene, IkBa. IkBa mRNA was up-regulated by 
BSO and paclitaxel treatments and the effect was reverted by NAC and SC514 co-
treatments (Fig. 2C). Strikingly, SC514 also reduced Pdl1 mRNA in BSO- or paclitaxel-
treated BMDM (Fig. 2D). Then we sought to validate that SC514-mediated effect on PD-L1 
was indeed mainly NF-kB dependent. To do so, we analysed the expression of IkBa, 
vascular endothelial factor-A (Vegfa) and PD-L1 in BMDM treated with BSO and paclitaxel 
combined with an inhibitor of aryl-hydrocarbon receptor (AhRi). AhR is a transcription factor 
involved into ROS detoxification, growth factor signalling and can cross-talk with NF-kB 
pathway(38). AhR inhibition impaired BSO- and paclitaxel-regulated Vegfa as previously 
described(39, 40)but did not affect IkBa or Pdl1 increased levels (SI Appendix, Fig. S3C).  
SC514 also affected PD-L1 cell surface expression in CD206+MHC-II- BMDM (Fig. 2E and 
SI Appendix, Fig. S3D).  
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Our data showed a novel mode of regulation of PD-L1 by NF-kB via ROS. We found that 
ROS induced p65 phosphorylation at a level similar to LPS (Fig. 2A,B). PD-L1 has been 
previously identified to be regulated in BMDM by LPS-induced NF-kB activation (41). By 
analyzing the same gene dataset, we confirmed that PD-L1 expression increased in LPS-
treated BMDM and positively correlated with Nfkb1/p65 and Rela/p50 mRNA levels (SI 
Appendix, Fig. S3E). Moreover, the link between NF-kB and mouse PD-L1 gene 
transcription was reinforced by the identification of a Nfkb1/p65 binding enhancer (I1551) 
through bioinformatics analysis of the inflammatory gene expression program in 
macrophages(42)(Fig. 1F). By chromatin immunoprecipitation followed by quantitative PCR 
(ChIP-qPCR) we found a significant enrichment of p65 at I1551 site in the Pdl1 promoter at 
1h after paclitaxel treatment that was reverted by NAC (Fig. 2G). In the same conditions, 
p65 failed to bind the promoter of the NF-kB target, IL-6, suggesting a specificity in gene 
transcription activation by NF-kB upon high ROS.   
 
Paclitaxel promotes PD-L1 expression in tumor-associated macrophages in vivo 
Through bioinformatics analysis of TCGA human database of both Basal BC and BC with 
homologous recombination DNA repair defects (HR-defective BC, see Materials and 
Methods for additional details), we found that cancer-associated PD-L1 positively correlated 
with an elevated infiltration of monocytic lineage cells (monocytes and macrophages) in the 
TME (SI Appendix, Fig. S4A)(43). To test if paclitaxel could induce PD-L1 expression in 
TAM, we took advantage of a mouse mammary tumor cell line carrying BRCA1/Trp53 
deletion and resembling human TNBC (hereafter referred to as KBP)(44). These cells form 
palpable tumors once transplanted in the mammary fat pad of immune-proficient female 
mice, allowing analysis of both tumor and immune cell populations in the TME, including 
TAM. We administrated vehicle and paclitaxel intravenously at 20mg/kg to mice bearing 
tumors at a palpable and measurable size (70mm3). Tumors were harvested and dissociated 
for flow cytometry analysis both at 24h and 5 days post-treatment. In CD206+MHC IIlow TAM, 
PD-L1 surface expression did not change at 24h post-treatment but showed a significant 
increase at 5 days after paclitaxel injection, even if we noticed a slight increase of Pdl1 in 
tumors from vehicle treated mice, likely due to the tumour mass progression from 70mm3 to 
about 200-300mm3 (Fig. 3A and SI Appendix, Fig. S4B). Indeed, in vitro co-cultured BMDM 
with KBP cells displayed an ncrease in Pdl1 and arginase 1 (Arg1) expression after being 
in contact with tumor cells (SI Appendix, Fig. S4C,D. These results postulate that TAM are 
instructed in situ by tumour cells to express Pdl1 during tumour progression. We found that 
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circulating monocytes in tumor bearing mice either untreated or paclitaxel-treated expressed 
very low to undetectable levels of PD-L1 (Fig. 3B and SI Appendix, Fig. S4E). 
Then, we asked the question if PD-L1 expression correlated with ROS levels in CD206+TAM 
as found in BMDM. At 5 days post-treatment, we stained CD206+TAM for DCF-DA to 
measure intracellular ROS. Strikingly, we observed an increased positivity for DCF-DA in 
the PD-L1+ macrophages, validating the link between cellular redox status and PD-L1 levels 
found in vitro (Fig. 3C). It is reported that paclitaxel treatment is also able to induce PD-L1 
expression in tumor cells, including the TNBC cell line MDA-MB-231 and a panel of ovarian 
cell lines(45-47). Therefore, we investigated PD-L1 levels in CD45-CD49f+ KBP mammary 
tumor cells as we did in TAM. We did not observe any increased PD-L1 positivity within 
mammary tumor epithelial cells, either 24h or 5 days post treatment (Fig. 3D and SI 
Appendix, Fig. S4F). In vitro treatment of same KBP cells with increasing doses of paclitaxel 
induced a very marginal increase in PD-L1 surface expression after 24h (SI Appendix, Fig. 
S4G). Consistent with the in vitro results from BMDM cytokine array, TAM from paclitaxel-
treated tumors produced higher levels of IL-10 and IL-17 and lower amount of IL-12 (Fig. 
4E-G and SI Appendix S4H).  
To investigate the involvement of NF-kB in PD-L1+ TAM in vivo, we analysed CD206+ PD-
L1+ TAM for the presence of phosphorylated p65 in both paclitaxel-and vehicle-treated KBP 
allografts. At 5 day time point, when PD-L1 surface expression was high, these 
macrophages also showed an increase in p65 phosphorylation, suggesting activation of NF-
kB pathway in the same cellular compartment (Fig. 3E and SI Appendix, Fig. S4H). Overall, 
both in vitro and in vivo data elucidate a link between paclitaxel, ROS accumulation and NF-
kB activation in macrophages. We corroborated this signaling pathway by bioinformatics 
analysis of TCGA Basal and HR-defective BC cohorts. In these datasets, we looked for 
correlation between expression signature of human BC-infiltrating TAM(48, 49), our key 
genes of interest (i.e., PD-L1 and NFKB1/p65) and a comprehensive ROS-induced gene 
signature(50). We investigated gene correlations in the expression profiling of both M1 and 
M2 compartments identified in the two published studies(48, 49). These studies elucidated 
that macrophages express M1 and M2-type gene modules simultaneously and M1 and M2 
genes positively correlate in macrophages, contrary to models supporting mutually exclusive 
M1 and M2 subsets(49). We found that in both Basal and HR-defective BC cohorts, M1 and 
M2 signatures positively correlated with expression of PD-L1, NFKB1/p65 and activation of 
ROS signaling pathway (Fig. 3F and SI Appendix, Fig. S4I).  
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PD-L1 blockade potentiates anti-tumor effects of paclitaxel in vivo 
Several ongoing clinical trials in TNBC patients are currently exploring the effectiveness of 
combining paclitaxel treatment with immune checkpoint inhibitors as compared to single 
agent therapy(7, 51, 52). We hypothesized, based on our in vitro and in vivo observations, 
that inhibition of PD-L1 could revert the immune-suppressive and tumorigenic properties of 
TAM to enhance the anti-tumor activity of paclitaxel. We first assessed if the use of anti-PD-
L1 antibody (PD-L1) could affect the viability of BMDM whether alone or in combination 
with paclitaxel in vitro by SRB assay. Isotype-treated cells were included as control. We did 
not notice any difference in cell viability in both groups over 5 days treatment (SI Appendix, 
Fig. S5A). In addition, we did not find any changes in the surface expression of CD206 and 
MHC-II, in both treated- or control cells (SI Appendix, Fig. S5B,C). PD-L1 also did not affect 
paclitaxel-induced Pdl1 mRNA increase (SI Appendix, Fig. S5D).   
Then, we investigated if PD-L1 blockade could influence the production of cyokines in 
BMDM. Interestingly, we found that PD-L1 inhibition restored all the paclitaxel-induced 
cytokines to control level (Fig. 4A). Vegfa mRNA levels were also negatively affected by 
PD-L1/paclitaxel combination compared to isotype/paclitaxel (Fig. 4B).  
These in vitro data prompted us to investigate the anti-tumor effect of PD-L1 in the KBP 
mouse model in combination with paclitaxel. We administrated paclitaxel (intravenously) and 
PD-L1 (intraperitoneally) either in combination or as single agents. First, mice were treated 
with paclitaxel (to induce PD-L1) and then with PD-L1 as summarized in Fig. 4C. Since 
paclitaxel was administrated once a week, we performed an additional injection of PD-L1 
to guarantee PD-L1 blockade. Both compounds were administrated when mammary tumors 
reached a palpable and measurable volume (70mm3). Tumor-bearing mice were monitored 
until they reached humane endpoint (tumor volume≤ 2cm3). Combinatorial treatment of KBP 
mice with paclitaxel and PD-L1 significantly reduced both tumor volume and weight as 
compared to control mice (Fig. 4D,E). On the contrary, the administration of either paclitaxel 
or PD-L1 as monotherapy did not show any effect (Fig. 4D,E). Haemotoxylin and Eosin 
(H&E) staining of KBP allografts showed that all treated tumors had a reduced mitotic index 
compared to tumors from vehicle+isotype mouse group (Fig. 4H). We did not find any 
difference in blood vessel density based on immunohistochemical staining of the platelet 
endothelial cell adhesion molecule PECAM1/CD31 (SI Appendix, Fig. S5E). Compared to 
paclitaxel alone, co-treatment with PD-L1 blockade significantly impaired P-p65 signal and 
increased cleaved caspase 3 (Fig. 4I,J and SI Appendix, Fig. S5F,G). 
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Paclitaxel combined with PD-L1 blockade leads to anti-tumor immune activation 
To evaluate the immune response in the KBP allografts, we collected and analysed tumors 
from all mouse group at endpoint for immune cell infiltrates. We observed a moderate 
reduction in the percentage of F4/80+/CD11b+TAM in the PD-L1/paclitaxel group, probably 
due to reduced infiltration in the TME rather than increased TAM cell death (Fig. 5A). Then, 
we looked at the impact of PD-L1/paclitaxel regimen on different T cell populations. aPD-
L1/paclitaxel-treated tumors restored the number of CD4+T cell that were reduced by 
paclitaxel alone (SI Appendix Fig. S6A, B). Within the CD4+ population, we found a reduced 
percentage of immune-suppressive CD4+ regulatory cells (as defined by FoxP3 and CD25 
marker staining) in the tumors isolated from PD-L1/paclitaxel-treated group. CD4+FoxP3+T 
were dramatically affected by PD-L1 alone as previously published (53)(SI Appendix Fig. 
S6C). While paclitaxel alone did not affect CD8+ population, these cells were moderately 
reduced in tumors from PD-L1/paclitaxel cohort (SI Appendix Fig. S6D). To better 
characterize the phenotype of CD8+T cells, we stained them for CD44/CD62L markers. 
PD-L1/paclitaxel-treated tumors contained a higher percentage of CD8 effector (CDeff) 
cells than all other tumors (Fig. 5B,C and SI Appendix Fig. S6E). In the same tumors, CD8+T 
cells presented the highest expression of interferon-gamma (IFN-), granzyme-B (GrnzB), 
PD-1 and CD107a and, confirming their activation and cytotoxic activity in the TME (Fig. 5D-
G and SI Appendix Fig.S6F-I). 
  
DISCUSSION 
The recent success of PD-1/PD-L1 blockade has renewed interest in immunotherapies, and 
in combining them with chemotherapy to achieve additive or synergistic clinical activity. 
Clinicians are currently exploring these combinatorial strategies for the treatment of TNBC, 
a very aggressive form of BC with poor prognosis. In TNBC, the expression of PD-L1 is 
almost undetectable in ductal carcinoma in situ (DCIS) tumor epithelial cells but increases 
to a higher extent in invasive ductal carcinoma (IDC) with the amplification of the CD274 
locus encoding PD-L1 in about 30% of the cases(53). This important finding suggests that 
in TNBC, TME immune-suppressive functions progressively change during tumor evolution. 
Together with anthracyclines, taxanes (including paclitaxel) are currently used as first-line 
therapy with variable success and frequent cases of relapse(1). The expression of PD-L1 in 
tumor and tumor-infiltrating cells in TNBC patients suggest that PD-L1 blockade may be a 
useful strategy to potentiate the anti-tumor effects of taxanes. Indeed, several clinical trials 
are currently exploring the combination of taxanes with PD-L1 inhibitors in TNBC(52). Very 
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recently, the primary results of one of these trails, IMpassion130, a phase III trial of an anti-
PD-L1 or anti-PD-1 antibody, have been reported in patients with metastatic TNBC(54). 
Although the study has not reached statistical significance yet, numerical increases in 
median overall survival were clearly observed in both the randomized population and in the 
subgroup where PD-L1 expression was assessed in tumor-infiltrating cells(54). One of the 
most important findings of this work is that PD-L1 expression levels in the tumor-infiltrating 
cells should be taken in consideration to guide treatment strategies in TNBC. Our data 
reporting the regulation of PD-L1 expression by paclitaxel in macrophages and TAM align 
with this result. Although PD-L1 expression has been generally considered to be induced at 
the transcriptional level after exposure to IFN-γ released by T effector cells(55), novel ways 
of transcriptional regulation of PD-L1 are emerging in both immune and tumor cells(19, 46). 
Here we have shown that in macrophages, PD-L1 levels respond to intracellular redox 
imbalances caused by both metabolic alterations such as deprivation of antioxidants and 
chemotherapy such as taxane. Overall, these data suggest a scenario where any 
intracellular or extracellular stresses affecting TME redox status can influence the 
communication between tumor cells and the surrounding immune system. In these settings, 
TAM responds to chemotherapy-induced ROS by upregulating PD-L1, releasing VEGF-A to 
promote angiogenesis and suppressing T cell mediated anti-tumor response. This suggests 
that administration of immunotherapy could potentiate paclitaxel efficacy by interfering with 
the immunosuppressive abilities of macrophages established by paclitaxel itself. Indeed, 
combinatorial PD-L1 and paclitaxel therapy promotes the anti-tumoral properties of TME 
by significantly increasing the percentage of tumor-infiltrating effector and cytotoxic CD8+T 
cells. Given the broad expression of PD-L1 in the TME, PD-L1 blockade may affect a wide 
range of cells, including tumor cells, T and B cells, natural killer, dendritic dells and 
macrophages(56). However, in our in vivo tumor model, ROS specifically increase PD-L1 in 
the macrophage compartment. Remarkably, it has been reported that TAM interfere with the 
cytotoxic activity of paclitaxel and TAM depletion potentiates the anti-tumor effect of the 
paclitaxel(57-59). In conclusion, our work has revealed a unique scenario that further 
supports the combination of PD-L1 blockade with taxane for the treatment of TNBC patients.    
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Materials and Methods  
Mice 
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K14cre BRCA1f/f p53f/f (KBP) mice were provided by Dr. J. Jonkers (NKI, Amsterdam, The 
Netherlands) and were on the FVB background. KBP tumor cells were obtained and used 
for in vivo transplantation studies as previously described(44). For KBP transplantation 
studies, FVB recipient female mice were 8-10 week old and were purchased from The 
Jackson Laboratory. Mice were maintained and handled according to protocols approved 
by the Animal Care and Use Committee of the University Health Network (UHN; Toronto, 
Canada).  
Preparation of murine bone marrow-derived macrophages (BMDM)  
Whole bone marrow was harvested from 10-12 weeks old female mice by flushing Hanks' 
Balanced Salt Solution (HBSS) through femurs and tibias using a 27-gauge needle (BD 
Biosciences). Following red blood cell lysis, cells were cultured in 10% RPMI in 10cm plates 
overnight. Non-adherent cells were collected and seeded in petri dishes in medium 
containing 20 ng/ml mouse macrophage colony-stimulating factor (M-CSF; PeproTech). 
After 3 days of culture, cell media was replenished with media containing 20ng/ml M-CSF. 
Macrophages were harvested on day 4 and used for all the in vitro assays described in the 
manuscript. Polarization toward alternative-activated macrophages was obtained by 
culturing BMDM with medium containing 20 ng/ml IL-4 (PeproTech) and 20 ng/ml M-CSF 
(PeproTech) for 24 h. For co-culture experiments, BMDM (1x106) were seeded in triplicate 
in 6-well plates and incubated with or without KBP cells (2.5x105 cells/well). Cells were 
harvested 24h later using enzyme-free cell dissociation medium (Millipore) and sorted on 
an Astrios FACS Instrument (Beckman Coulter). 
Preparation of human macrophages  
To generate human macrophages, CD14-positive monocytes were isolated from PBMCs 
from healthy donors (obtained from the Princess Margaret Cancer Center blood donor 
center) using human CD14 microbeads (Miltenyi Biotech). Monocytes were cultured in 
DMEM plus 10 % FBS (Gibco), and 100 U/ml penicillin and streptomycin in the presence of 
recombinant human M-CSF (PeproTech) at 50ng/ml. After 5-7 days, the differentiated 
macrophages were characterized by flow cytometry and used in all the reported 
experiments.   
KBP mammary tumor induction and treatment 
KBP cells (3x105) were transplanted into #4 mammary gland fat pads of syngeneic female 
FVB recipient mice (10 weeks old). Diameters of developing tumors were measured in 
duplicate using digital calipers starting on day 14 post-transplantation. Tumor volume (mm3) 
was calculated as ½(width2 * height). Tumor diameters were measured, and volumes 
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calculated as above three times per week. For experiments with Paclitaxel, anti-PD-L1 
antibody (10F.9G2; BioXCell) or Isotype Control (LTF-2; BioXCell) antibodies, KBP 
transplanted female mice were monitored until tumors reached a volume of 70mm3 and 
randomized. Mice were injected intravenously with Paclitaxel (20mg/kg, Medkoo) or vehicle 
(saline) once a week. When needed, the same mice were administrated with mouse anti-
PD-L1 antibody (200g/mouse) or its isotype control (200g/mouse) twice a week 
intraperitoneally. Paclitaxel was purchased in a powder form and dissolved in a solution of 
ethanol/cremophor EL/1X PBS (1:1:18). Both anti-PD-L1 and isotype antibodies were 
diluted in appropriate dilution buffers that were provided by the manufacturer.  
Mouse mammary tumor dissociation 
Tumors were resected from #4 mammary fat pads of transplanted mice, cut into 2-3mm2 
pieces, and placed into a C-tube (Miltenyi Biotech) containing 5 ml Iscove's Modified 
Dulbecco's Medium (IMDM) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 0.05 mM β-mercaptoethanol, 0.26 U/ml Liberase TM 
(Sigma), and 20 U/ml DNase I (Sigma). Tumors were mechanically processed using a 
gentleMACS Octo Dissociator with Heaters (Miltenyi Biotech). Processed samples were 
filtered once through a 100 µm cell strainer (Falcon), and the corresponding C-tubes were 
rinsed with 5 ml cold IMDM and passed through the same strainer. Cells were filtered once 
using a 70 µm strainer (Falcon), followed by a 40 µm strainer (Falcon). Filtered samples 
were collected in 15 ml Falcon tubes and centrifuged at 1250 RPM for 8 min at 4°C. Pellets 
were incubated with red blood cell lysis buffer for 7 min at room temperature (RT), and then 
centrifuged at 1250 RPM for 8 min at 4°C before resuspension in 1X PBS-/- containing 1% 
bovine serum albumin (BSA) plus 2 mM ethylenediaminetetraacetic acid (EDTA). Cell 
suspensions were subjected to fluorescence-activated cell sorting (FACS)/flow cytometry 
as described below. 
Flow cytometry 
For mouse tumor-associated macrophages and BMDM, cell surface marker staining for flow 
cytometry analysis was performed using the following antibodies (Abs), all from BioLegend 
unless indicated: anti-CD49f (AF488 GoH3; 1/200), anti-CD45.1 (AF700 A20; 1/400), anti-
CD11b (Pacific Blue M1/70; 1/400), anti-F4/80-PE (BM8; 1/400), anti-F4/80-PerCP-Cy5.5 
(BM8; 1/200), anti-MHC II (IA/IE)-PE (M5/114.15.2; 1/1600; Thermo Fisher Scientific), anti-
CD206-AF647 (C068C2; 1/400), anti-PD-L1-Pe-Cy7 (10F.9G2; 1/400), anti-CD3-AF488 
(145-2C11; 1/250), anti-CD8-APC-Cy7 (53-6.7; 1/200), anti-CD4-PerCP-Cy5.5 (RM4-5; 
1/800), anti-CD25-PE (PC61; 1/200), anti-IFN-APC (XMG1.2; 1/200), anti-Granzyme B-PE 
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(GB11; 1/200), anti-TNF-PE-Cy7 (MP6-XT22; 1/800), anti-CD107a-BV421 (1D4B; 1/800), 
anti-CD62L-PE-Cy7 (MEL-14; 1/800; Thermo Fisher Scientific), anti-CD44-APC (IM7; 
1/800) and anti-PD1-PE (RMP1-30; 1/200; Thermo Fisher Scientific).  
For IFN- and GranzimeB staining, cells were stimulated with phorbol myristate acetate 
(PMA) (20 ng/ml, Sigma) and ionomycin (1 ug/m, Sigma) in presence of the intracellular 
protein transport inhibitor Brefeldin A (eBioscience). Cells were harvested 5h later and 
stained for surface markers as following. Cells were washed twice with 1X PBS-/-, fixed and 
permeabilized on ice for 30min with Intracellular Permeabilization kit (Thermo Fisher 
Scientific). After washing with the permeabilization buffer, cells were stained for IFN- and 
GranzimeB on ice for 30min. 
Mouse macrophages were identified as CD49flo/-CD45+CD11b+F4/80hi and mouse T cells 
as CD49flo/-CD45+CD3+. Mouse macrophages were treated with Mouse BD Fc BlockTM (anti-
CD16/CD32 2.4G2; eBioscience) at 1/100 dilution for at least 10 min prior staining with 
appropriate Abs. For human macrophages, cell surface marker staining was performed with 
PDL1 BV421 (29E.2A3; 1/400) and CD11b BV510 (ICRF44; 1/400), both from BioLegend.  
Human macrophages were treated with 1X PBS-/- containing 5% BSA and 2 mM EDTA for 
30 min on ice prior staining with Abs. For both mouse and human macrophages, Abs were 
prepared at the indicated dilutions in 1X PBS-/- containing 1% BSA and 2 mM EDTA for 30 
min on ice. Dead cells were excluded by adding 5 μl of 7-AAD (BioLegend) during the last 
10 min of staining with the Abs. Cells were then washed twice and further analyzed.  
To quantify intracellular cytokine production, mouse mammary tumor cells suspensions 
were treated with phorbol myristate acetate (PMA) (5 ng/ml, Sigma) and ionomycin (500 
ng/m, Sigma) in presence of the intracellular protein transport inhibitor Brefeldin A 
(eBioscience) and Monensin (eBioscience), for 4 hours prior to staining. The cells were fixed 
and permeabilized prior to immunostaining for IL-12 PE (C15.6; 1/400; BD), IL-17 (TC11-
18H10.1; 1/400; BioLegend) and IL-10 (JES5-16E3; 1:400; BioLegend). Positivity were 
assessed among live CD45+CD11b+F4/80+ cells. All samples were analyzed at Fortessa 
Instrument (BD Biosciences) and data were processed with FlowJo (Tree Star, Inc.) and 
GraphPad software.  
Analysis of peripheral blood monocytes 
Peripheral blood (15μl) was first collected from mouse tail vein into heparinized capillary 
tubes, and then transferred into a 5 ml polystyrene tube containing 100 μl 1X PBS-/- plus 20 
mM EDTA. After blocking with anti-CD16/CD32 abs (1:100) for 10 min, samples were 
stained with anti-CD11b-Pacific Blue and anti-PD-L1-PE-Cy7 as described above. Samples 
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were washed twice 1X PBS-/- containing 1% BSA and 2 mM EDTA. Red blood cells were 
lysed at room temperature for 10 min with 1ml of Fix/Lyse solution (ThermoFisher). Cells 
were washed twice with 1X PBS-/- and analyzed at Fortessa Instrument (BD Biosciences). 
Data were processed with FlowJo (Tree Star, Inc.) and GraphPad software.  
Phospho-P65 staining by flow cytometry 
Tumors were dissociated according to mouse mammary tumor dissociation method. 
106cells were suspended in 0.5 ml of 1X PBS and immediately fixed with 0.5 ml of 4% 
formaldehyde (final concentration 2%) at 37°C for 10 min. Cells were washed by 
centrifugation with 1X PBS-/- containing 1% BSA and 2 mM EDTA prior staining with anti-
CD45.1 (AF700 A20; 1/400), anti-CD11b (Pacific Blue M1/70; 1/400), anti-F4/80 (PE BM8; 
1/400), anti-CD206 (Fitc C068C2; 1/400) and anti-PD-L1 (Pe-Cy7 10F.9G2, 1/400) (see flow 
cytometry method for additional details). Cells were washed twice with 1X PBS-/- containing 
1% BSA and 2 mM EDTA and permeabilized by slowly adding ice-cold Perm Buffer II 
(eBioscience) with gentle vortexing. Cells were incubated on ice for 30 min and washed 
twice. Cells were then suspended in 100ul of primary phospho-p65 (Ser536) antibody 
(93H1, 1/1600, Cell signaling) or isotope control (rabbit IgG, 1/1600, Thermo Fisher 
Scientific) and incubated on ice for 1h. After two washes, cells were resuspended in 100ul 
of secondary antibody (goat anti-rabbit APC coniugated, Thermo Fishes Scientific) diluted 
1/500 and incubated on ice for 1h. Cells were then washed twice and analyzed at Fortessa 
Instrument (BD Bioscience) and data were processed with FlowJo software (Tree Star, Inc.).  
Phospho-P65 staining by immunofluorescence 
For analysis of p65 S536 phosphorylation, 2x105 BMDM were seeded in a 12 well plate 
containing glass coverslips. The day after, cells were treated with BSO (200M) and 
Paclitaxel (100nM) in the presence or absence of SC514 (50M) for 3h. Cell treatment with 
Lipopolysaccharide (LPS) at 1mg/ml for 30min was included as positive control of p65 S536 
phosphorylation. After treatments, cells were fixed with 4% PFA for 15 min at 37°C. Cells 
were then stained overnight at 4°C with primary antibody (93H1, 1:1600, Cell Signaling). 
The following day, cells were washed three times and subjected to FITC-conjugated 
secondary antibody (A-11008, Thermo Fisher Scientific) at 1:1000 for 2hr RT. Nuclei were 
counterstained with DAPI (P36962, Thermo Fisher Scientific). To quantify phospho-p65 
nuclear fluorescence intensity, we randomly selected 100 nuclei for each sample and 
analyzed them with ImageJ software as following. First, we applied an otsu threshold to the 
DAPI channel to generate a mask marking the nuclear area. Then, with the tracing tool, we 
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transpose each mask to the FITC-positive channel to calculate the Mean Intensity in the 
nuclear region.  
Cell lines and treatments 
Mouse KBP cells were cultured in DMEM/F12 medium containing 10% FBS (Thermo Fisher 
Scientific), L-glutamine, 1 µg/ml hydrocortisone (Sigma), 5 µg/ml insulin (Sigma), 5 ng/ml 
epidermal growth factor (EGF, Sigma) and penicillin-streptomycin (Pen-Strep, 
ThermoFisher Scientific). Human macrophages were cultured in DMEM medium 
supplemented with 10% FBS (Thermo Fisher Scientific), L-glutamine and penicillin-
streptomycin (Pen-Strep, Thermo Fisher Scientific). The glutathione synthesis inhibitor, 
buthionine sulfoximine (BSO, Sigma) was used at 200 µM (BMDM) or 1mM (human 
macrophages) for specific period of times as indicated in the main manuscript. 
Chemotherapeutic drugs were administered in vitro at the following concentrations: 100nM 
(Paclitaxel, Medkoo), 0.5M (Olaparib, Medkoo) and 2M (Cisplatin, Medkoo). Anti-PD-L1 
mouse or Isotype control antibodies were both used at 10g/ml (BioXCell). For ROS 
scavenging, BSO or paclitaxel-exposed cells were co-treated with 1mM NAC (SIGMA). The 
NF-kB antagonist SC514 (Sigma) was applied to cell cultures at 50M. The AhR inhibitor, 
CH-223191 (MedKoo) was used at 10M for 24h. 
Sulforhodamine B (SRB) colorimetric assay  
BMDM were seeded at 8000cells/well in triplicate. The day after, cells were treated with 
Paclitaxel at 100nM or DMSO for 24h. The following day, anti-PD-L1 or isotype control 
antibodies were added to the cells at 10g/ml. Cells were stained with Sulforhodamine B 
every 24h and processed accordingly to the manufacturer’s recommendations. Cell density 
was calculated using the SoftMax Pro software (Molecular Devices).  
Mouse Cytokine array 
Mouse Cytokine Antibody Array kit (Abcam) was performed to measure chemokines, 
cytokines and growth factors in the culture media of BMDM and according to manufacturer’s 
instructions. Membranes were developed for chemiluminescent detection and images were 
acquired with GelCapture Software using MicroChemi 2.0/4.2 (FroggaBio).   
RT-PCR 
RNA was isolated using the Nucleospin RNA Plus kit (Macherey-Nagel) and reverse-
transcribed using the iScript cDNA synthesis kit (Bio-Rad) according to manufacturers’ 
instructions. Quantitative RT-PCR was performed using SYBR Green primers (Applied 
Biosystems). Mouse and human ribosomal proteins S9 (rps9) were used as housekeeping 
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genes to calculated relative mRNA expression. All mouse and human primer sequences are 
described in SI Appendix Table 1. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) assay was performed using SimpleChip® Plus 
Enzymatic Chromatin IP Kit (#9003, Cell Signaling Technology). 8 × 106 BMDM were left 
untreated or treated with 100nM paclitaxel with or without 1mM NAC for 1 h. Chromatin was 
prepared by enzymatic shearing according to the manufacturer’s instructions. 
Immunoprecipitation was performed at 4°C overnight with 0.75μg NF-κB p65 Ab (L8F6, Cell 
Signaling) and 1μg mouse IgG as negative control. Following immunoprecipitation, samples 
were incubated with Chip-Grade protein G Magnetic Beads from Kit at 4°C for 2 h. The 
cross-linking was reversed by adding 5 M NaCl and proteinase K at 65°C for 2 h. Real-time 
PCR was performed on DNA isolated from each ChIP reactions (n=3) using Power SYBR 
Green PCR master mix. Primers are indicated in SI Appendix Table 1.  
ROS measurement 
To measure intracellular ROS, 2x105 BMDM were incubated with 300 nM CM-H2DCFDA 
(DCF-DA, C6827, Invitrogen) for 10 min at 37°C. DCF-DA fluorescence was analyzed by 
flow cytometry using a FACS Fortessa (BD Biosciences) and data were processed with 
FlowJo software. 
DNA damage measurement 
To measure intracellular DNA damage, 2x105 BMDM were fixed and permeabilized with BD 
Cytofix/Cytoperm (BD Biosciences). Then, cells were stained with FITC-conjugated -H2AX 
(1/400; Millipore) for 1h, washed twice and analyzed by flow cytometry using a FACS 
Fortessa (BD Biosciences). Data were processed with FlowJo software. 
Immunohistochemistry 
Tissue sections were cut from frozen tissue specimens in OCT 8-10um thick. Slides were 
dried overnight and immunohistochemistry performed the next day. Slides were briefly 
washed in PBS followed by 15min in 0.3% hydrogen peroxide-PBS to quench endogenous 
peroxidases. Slides were then washed in PBS before applying a histoblock solution (HB: 
BSA, MgCl2, 0.2% Tween20) for 30min. Slides were drained and anti-p65 antibody (93H1, 
1:100, Cell Signaling) was applied and incubated overnight at 4C. The following day, slides 
were washed and secondary Ab applied for 30min (goat anti-rabbit secondary, BA-1000, 
VectorLabs). ABC reagent (PK-6100, VectorLabs) was applied for 25min following 
development with DAB (SK-4100, VectorLabs). Specimens were viewed with a brightfield 
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microscope (Leica DM2500 equipped with Micropublisher 3.3-QI imaging camera) using Q-
Capture Pro Software and processed with Adobe Photoshop CS5. 
Cleaved caspase 3 staining   
Tissue specimens from treated mouse cohorts were processed for cleaved caspase 3 
immunohistochemical staining as following. Antigen retrieval was perfomed with microwave 
heating in 10mM Na citrate (pH 6.0) treatment for 25 min. The primary Ab was prepared in 
histoblock solution (3% BSA, 20mM MgCl2 ,0.3% Tween 20 in 1X PBS with 5% goat serum with 
0.2% Triton X-100 at a dilution of 1:1000 overnight at 4ºC. Secondary Ab (goat anti-rabbit, Vector 
labs BA-4001) was incubated for 1h min at a dilution of 1:400. Signal was visualized with DAB 
Peroxidase reagent (Vector labs kit SK-4100). Slides were digitized using a Nanozoomer2.0 HT-
Hamamatsu (Olympus). An image analysis protocol (APP) was developed using Visiopharm 
software (Visiopharm, Denmark) to identify the cells that were positive for cleaved caspase 3. A 
ratio of positive cells to total cell number was then calculated for each slide.  
Analysis of mouse BMDM databases 
Unsupervised clustering of Pdl1, Nfkb1/p65, and Rela/p50 gene expression profiles in mouse 
BMDM exposed to LPS (data from GEO reference GSE27112) (41). The Spearman’s correlation 
coefficients (SCCs) of Cd274 and the two other genes are shown. Mouse genomic region 
including the Pdl1 gene and depicting the Nfkb1/p65 chromatin immunoprecipitation results in 
BMDM untreated or exposed to LPS (two assays indicated in yellow and green; GEO reference 
GSE16723)(60). The positions of the Nfkb1/p65 enhancer described in Ghisletti et al. 2010 and 
validated by ChIP-qPCR is also indicated in blue(42). 
Analysis of human breast cancer datasets 
In TCGA database, Pam50 calls annotated in clinical data were used to identify primary breast 
tumors of the basal subtype. HR-deficient BC cohort was defined by using TCGA breast 
cancer RNAseq data and somatic mutations after being obtained following approval by the 
Data Access Committee (project #11689). The results published here are partly based upon 
data generated by TCGA managed by the National Cancer Institute and the National Human 
Genome Research Institute. Information about TCGA can be found at 
http://cancergenome.nih.gov. Mutational signatures were defined using the R mut 
Signatures package(61). The expression signature scores were computed using the 
ssGSEA algorithm with standard parameters and using all genes included in each set(62). 
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The PCC and p-values were computed in R, and immune cell types were inferred using the 
Microenvironment Cell Populations-counter (MCP-counter) method(43). The 
“Chuang_oxidative_stress_response” gene set (ROS up-regulated genes only) was chosen 
because it includes a highly comprehensive gene expression signature derived from the 
cellular response to three different oxidants, including hydrogen peroxide, menadione, and 
t-butyl hydroperoxide(50). 
Statistical analyses 
Data were reported in bar graphs as the mean or median ± standard error of the mean 
(SEM), with p-values calculated using Student’s t-test (*≤0.05, **≤0.01, ***≤0.001). The 
mean was calculated based on a minimum of n=3 replicates in each experiment, and each 
experiment was performed at least 3 times. Data were analyzed either by Microsoft Excel 
or GraphPad Prism 7. 
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FIGURE LEGENDS  
Figure 1: ROS regulate PD-L1 expression and secretion of immunosuppressive cytokines in 
BMDM. (A) Pdl1 mRNA levels in BMDM obtained from FVB mice (n=4/group). Cells were left 
untreated (Ctrl) or treated for 24h with BSO (200M)±NAC (1mM). (B) Gclc and Gclm mRNA 
levels in BMDM treated as in (A). n=4/group. (C, D) Percentage of PD-L1 positive BMDM gated 
on live CD45+ CD11b+ F4/80+ within CD206+MHC-II- (C) or CD206-MHC-II+ (D) populations. 
Cells were isolated from n=3 FVB mice and analyzed after being treated as in (A).  (E) Levels of 
indicated chemokines in the supernatant of BMDM, as determined by cytokine antibody array 
after treatment with BSO (200M)±NAC (1mM) for 24h. Values are the mean of biological 
duplicates and are represented as ratio to untreated control. (F) Pdl1 mRNA levels in BMDM that 
were exposed to DMSO (Ctrl) or paclitaxel (100nM)±NAC (1mM) for 24h. n=4/group. G) Gclc 
and Gclm mRNA levels in BMDM treated as in (F). (H, I) Percentage of PD-L1 positive BMDM 
gated on live CD45+ CD11b+ F4/80+ within CD206+MHC-II- (H) or CD206-MHC-II+ (I) 
populations. Cells were isolated from n=3 mice treated as in (F). (J) Levels of indicated 
chemokines in the supernatant of BMDM as determined by cytokine antibody array and treated 
as in (F). Values are the mean of biological duplicates and are represented as ratio to DMSO-
treated control cells. Data in A-D and F-I are presented as mean ± S.E.M of biological replicates. 
*P≤0.05, **P≤0.01,***P≤0.001. 
Figure 2: ROS-induced PD-L1 expression is mediated by the transcription factor NF-kB. (A) 
Relative number of cells containing p65 S536 phosphorylation (P-p65) as assessed by 
immunofluorescence staining of BMDM that were treated with DMSO (Ctrl) and BSO (200M) 
or paclitaxel (100nM) + SC514 (50M) or NAC (1mM). Cells stimulated with LPS for 30min were 
used as positive control. n=4 slides/group. A total number of 100 cells were counted in each slide. 
The bar graph represents the mean of all values ± S.E.M. (B) Nuclear signal intensity of P-p65 in 
cells treated and presented as in (A). See Material & Methods for additional details. (C) IkBa 
mRNA levels in BMDM treated as in (A). (D) Pdl1 mRNA levels in BMDM left untreated or 
treated with DMSO (Ctrl) and BSO (200M) or paclitaxel (100nM) + SC514 (50M). (E) 
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Percentage of PD-L1 positive BMDM gated on live CD45+ CD11b+ F4/80+ within CD206+MHC-
II- cells after being treated as in (D). (F) Scheme showing NF-kB1/p65 binding sites on mouse Pdl1 
promoter region as found through bioinformatic analysis of GSE16723 and Ghisletti et al. 2010 
datasets. Yellow and green indicates two biological replicates of LPS-treated BMDM. The location 
of NF-kB1/p65 binding enhancer from Ghisletti et al. 2010 is indicated in blu. (G) ChIP-qPCR 
showing a peak of enrichment of p65 at I1551 enhancer in Pdl1 promoter region in BMDM 
treated with BSO for 1h. NAC reverted the BSO-mediated effect. n=3. Data in C-E and G are 
presented as mean ± S.E.M of biological replicates. *P≤0.05, **P≤0.01,***P≤0.001. 
Figure 3: Paclitaxel promotes PD-L1 expression in tumor-associated macrophages in vivo. (A) 
Percentage of PD-L1 positive cells gated on live CD49f- CD45+ CD11b+ F4/80+ CD206+ cells 
isolated from KBP tumors (n=5/group) after 24h and 5 days of treatment with paclitaxel 
(20mg/kg) or vehicle (saline). (B) Percentage of PD-L1 positive cells gated on live CD49f- CD45+ 
CD11b+ F4/80- cells from peripheral blood of KBP-bearing mice treated as in (A). n=5/group. (C) 
ROS intracellular measurement by DCF-DA staining of live CD45+ CD11b+ F4/80+ cells, gated 
accordingly to PD-L1 negative (PD-L1- ) or positive surface expression (PD-L1+). Cells were 
isolated from KBP tumors after 5 days of treatment with paclitaxel (20mg/kg). n=6/group. (D) 
Percentage of PD-L1 positive cells (PD-L1+) gated on live CD49f+ CD45- cells isolated from KBP 
tumors (n=5/group) after 24h and 5 days of treatment with paclitaxel or its vehicle. (E-G) Analysis 
of intracellular production of IL-10 (E), IL-17 (F) and IL-12 (G) in CD11b+F4/80+ isolated from 
vehicle- and paclitaxel-treated tumors at 5 day post-treatment. n=5. (H) Flow cytometric analysis 
of S536 phosphorylation in p65 in TAM isolated from tumor-bearing mice (CD49flow/-CD45+ 
CD11b+ F4/80+ CD206+ PD-L1+) at 5 days after treatment with paclitaxel or vehicle (n=6/group). 
Values are normalized on phospho-p65 levels in isotype control in both groups. (I) Positive 
correlation between M1 or M2 gene expression signatures (as determined by Chung et al, 2018 
and Azizi et al., 2018) and the expression levels of CD274, p65/NFKB1 and the “Chuang oxidative 
stress response” gene signature in the TCGA human basal-like BC cohort. See Material and 
Methods for details. Data in A-H are presented as mean ± S.E.M of biological replicates. *P≤0.05, 
**P≤0.01. 
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Figure 4: PD-L1 blockade potentiates anti-tumor effects of paclitaxel in vivo. (A) Levels of 
indicated chemokines in BMDM after treatment with vehicle, paclitaxel (100nM) with PD-L1 
antibody (10g/ml) or isotype control (10g/ml) for 24h. Values are the mean of biological 
duplicates and are represented as ratio to control cells treated with DMSO and isotype. (B) Vegfa 
mRNA levels in BMDM treated as in (A). (C) Schematic representation of paclitaxel and PD-L1 
treatment schedule for KBP tumor-bearing mice. Control group received vehicle and isotype. (D) 
Volume measurement of mammary tumors over time in mice transplated with KBP cells and 
treated accordingly to the regimen described in (C). (E) Weight of tumors isolated at humane 
endpoint post-treatment (day 14th). n=10-15/group. (F) Mitotic index by direct counting of 
mitotic cells in haematoxylin and eosin (H&E)‐stained tumor sections. n=5/group. (G) Mean of 
P-p65 signal calculated as Optical Density by ImageJ assessed by immunohistochemistry of KBP 
tumors. n=5/group. (H) Quantification of cleaved caspase 3 staining performed by 
immunohistochemistry of KBP tumors. n=10/group. Data in B-H are presented as mean ± S.E.M 
of biological replicates. *P≤0.05, **P≤0.01, ***P≤0.001. 
Figure 5: Paclitaxel and PD-L1 blockade combinatorial treatment promotes anti-tumor immune 
respose. (A) Percentage of CD11b+ F4/80+ cells gated on live CD49f- CD45+ cells isolated from KBP 
tumors at endpoint. n=10-15/group. (B) Percentage of CD8+ T cells gated on CD49f- CD45+ 
CD3+cells in control or treated cohorts (n=10-15/group). Cells were characterized based on the 
expression of CD44 and CD62L as following: naïve (CD44- CD62L+), memory (CD44+ CD62L+) or 
effector (CD44+ CD62L-). Percentages are represented as stacked bar graphs. For the CD8+ effector 
cells, statistical significance was determined by student t-test: vehicle+isotype versus 
paclitaxel+PD-L1 (*p=0.01), vehicle+PD-L1 versus paclitaxel+PD-L1 (*p=0.0152), 
paclitaxel+isotype versus paclitaxel/PD-L1 (**p=0.006). (C) Absolute numbers of CD8+ effector 
cells in control and treated cohorts (n=10-15/group). (D-G) Percentage of CD8+ T cells (gated on 
CD49f- CD45+ CD3+) that were positive for the expression of IFN GrnzB, CD107a and PD-1 as 
indicated in control or treated cohorts (n=10-15/group). Data in A-G are presented as mean ± 
S.E.M of biological replicates. *P≤0.05, **P≤0.01, ***P≤0.001. 
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Supplementary	Table	1:	Primers	used	for	qRT-PCR	and	ChIP-qPCR	(m=mouse)	(h=human).		
	
Gene	 Primer	Sequence	
mRsp9	F	 GCAAGATGAAGCTGGATTAC	
mRps9	R	 GGGATGTTCACCACCTG	
mNqo1	F	 AGGATGGGAGGTACTCGAATC	
mNqo1	R	 AGGCGTCCTTCCTTATATGCTA	
mHo-1	F	 AAGCCGAGAATGCTGAGTTCA	
mHo-1	R	 GCCGTGTAGATAATGGTACAAGGA	
mGclc	F	 GGCTCTCTGCACC	
mGclc	R	 GTTAGAGTACCGA	
mGclm	F	 AAGTTAACCTGGC	
mGclm	R	 GAGAGCAGTTCTT	
mPdl1	F	 CAGCAACTTCAGGGGGAGAG	
mPdl1	R	 TTTGCGGTATGGGGCATTGA	
mIkBa	F	 AACCTGCAGCAGACTCCACT	
mIkBa	R	 GACACGTGTGGCCATTGTAG	
mVegfa	F	 CCGGGCCTCGGTT	
mVegfa	R	 GGGACCACTTGGC	
hRsp9	F	 GTTTGCTTAGGCGCAGACG	
hRps9	R	 CCATACTCGCCGATCAGCTT	
hPdl1	F	 AAATGGAACCTGGCGAAAGC	
hPdl1	R	 GATGAGCCCCTCAGGCATTT	
hNqo1	F	 TCCCCCTGCAGTGGTTTGGAGT	
hNqo1	R	 ACTGCCTTCTTACTCCGGAAGGGT	
mIL-6	F	(ChIP)	 CACTTCACAAGTCGGAGGCT	
mIL-6	R	(ChIP)	 AATGAATGGACGCCCAGACT	
mPdl1-I1551	F	(ChIP)	 GCCAGGCAGAACTAAAGTGG	
mPdl1-I1551	R	(ChIP)	 GGTTCCTCAGGGTGACTCAG	
	
SI APPENDIX FIGURE LEGENDS 
Figure S1: ROS regulates PD-L1 mRNA and cell surface expression in BMDM. (A) 
Representative histogram profile of ROS levels in BMDM stained with DCF-DA and left 
untreated (Ctrl) or treated for 24h with BSO (200µM) + NAC (1mM). n=4/group. (B) Pdl1 
mRNA levels in BMDM that were treated with 20 ng/ml IL-4 and 20 ng/ml M-CSF (Ctr) or 
BSO (200µM) + NAC (1mM). n=3/group. (C) Arg1 mRNA levels in BMDM that were left 
untreated or treated with IL-4 and M-CSF as in (B). n=3/group. (D) Nqo1 and Hmox-1 
mRNA levels in BMDM that were left untreated (Ctrl) or treated for 24h with BSO (200µM) 
+ NAC (1mM). n=4/group. (E) PD-L1 mRNA levels in human macrophages that were left 
untreated (Ctrl) or treated for 24h with BSO (1mM) + NAC (1mM). n=3/group. (F) NQO1 
mRNA levels of human macrophages treated as in (B). n=3/group. (G) Percentage of PD-
L1 positive BMDM (gated on live CD45+ CD11b+ F4/80+) that were treated as in (E). n=3. 
(H) Percentage of PD-L1 positive BMDM gated on live CD45+ CD11b+ F4/80+ within 
CD206+MHC-II- or CD206-MHC-II+ populations. n=3. (I) Representative FACS plots of 
PD-L1 surface staining in CD206+MHC-II- or CD206-MHC-II+ populations treated as in 
(A). (J) Fold surface expression levels of PD-L1 in CD11b+ human macrophages treated 
as in (B). n=3/group. Data are normalized to values from untreated cells (Ctrl). Data in B-
H and J are presented as mean ± S.E.M of biological replicates. *P≤0.05, **P≤0.01, 
***P≤0.001. 
Figure S2: Paclitaxel-induced ROS regulates PD-L1 mRNA and cell surface 
expression in BMDM. (A) Left, representative histogram of intracellular ROS levels in 
BMDM as measured by DCF-DA staining. Cells were treated with DMSO (Ctrl), paclitaxel 
(100nM), olaparib (0.5µM) or cisplatin (2µM) for 24h. Right, quantification (n=4/group). 
(B) Left, representative histogram of DNA damage in BMDM stained for phosphorylated 
H2AX (g-H2AX) and treated as in (A). Right, quantification (n=4/group). (C) SRB assay in 
BMDM treated for 5 days with DMSO (Ctrl) and paclitaxel (100nM). (D) Representative 
histogram profile of ROS levels in BMDM stained with DCF-DA and left untreated (Ctrl) 
or treated for 24h with Paclitaxel (100nM) + NAC (1mM). n=4/group. (E) Pdl1 mRNA levels 
in BMDM that were treated with 20 ng/ml IL-4 and 20 ng/ml M-CSF (Ctr) or BSO (200µM) 
+ NAC (1mM). n=3/group. (F) Hmox-1 mRNA levels in BMDM treated with DMSO (Ctrl) 
or paclitaxel (100nM) + NAC (1mM). n=4/group. (G) Representative FACS plots of PD-L1 
surface staining in CD206+MHC-II- or CD206-MHC-II+ populations treated as in (D). (H) 
PD-L1 mRNA levels in human macrophages that were treated for 24h with DMSO (Ctrl) 
or paclitaxel (100nM) + NAC (1mM). n=3. (I) Surface expression levels of PD-L1 in 
CD11b+ human macrophages (n=3/group). Cells were treated as in (H) and values 
normalized to control (DMSO-treated cells). (J) NQO1 mRNA levels in human 
macrophages that were treated as in (H). n=3. Data in A, B, E, F and H-J are presented 
as mean ± S.E.M of biological replicates. *P≤0.05, **P≤0.01, ***P≤0.001. 
Figure S3: ROS-regulated PD-L1 expression depends on NF-kB transcriptional 
activity. (A) Representative images of BMDM positive for S536 phosphorylated-p65 (P-
p65) when treated with DMSO (Ctrl) or BSO (200mM) and paclitaxel (100nM) + SC514 
for 3h. Stimulation of BMDM with LPS for 30min was used as positive control for 
phosphorylated p65 (S536). The use of isotype control antibody was included as 
negative control. (B) Representative image of the analysis of P-p65 signal intensity 
performed by ImageJ. A mask defining the nuclear region (based on DAPI staining) was 
overlaid on FITC-positive image. The mean FITC signal intensity was then calculated in 
the defined area. (C) IkBa, Vegfa and Pdl1 mRNA levels in BMDM left untreated (Ctrl) or 
treated with BSO (200mM) and paclitaxel (100nM)+CH-223191 (10µM) AhR inhibitor for 
24h. n=3. (D) Representative FACS plot of PD-L1 surface expression in CD206+MHCII- 
BMDM. (E) Spearman’s correlation coefficients between mRNA expression levels of 
RelA/p50, Nfkb1/p65 and Pdl1 in GSE27112 dataset from BMDM that were stimulated 
with LPS at different time points. (F) ChIP-qPCR of p65 at IL-6 promoter region in BMDM 
treated with BSO+NAC for 1h. n=3. Data in C and F are presented as mean ± S.E.M of 
biological replicates. *P≤0.05, **P≤0.01, ***P≤0.001. 
Figure S4: Paclitaxel increases PD-L1 expression in tumor-associated 
macrophages in vivo. (A) Positive correlation between tumor-infiltration of monocytic 
lineage cells (monocyes and macrophages) and PD-L1 expression in the TCGA human 
basal-like and HR-defective BC datasets. See Materials and Methods for additional 
details. (B) Representative FACS plots of PD-L1 surface staining in TAM (CD49flow/-CD45+ 
CD11b+ F4/80+ CD206+MHC-IIlow) in tumors from mice treated with vehicle (saline) or 
paclitaxel (20mg/kg) for 24h and 5 days. (C,D) Pdl1 and Arginase1 mRNA levels in BMDM 
that were cultured alone or sorted after co-culture with KBP mammary tumor cells for 
24h in vitro. n=3. (E) Representative FACS plot of PD-L1 staining in CD11b+ cells from 
peripheral blood in tumour-bearing mice treated vehicle and paclitaxel for 24h and 5 
days. (F) Representative FACS plot of PD-L1 staining in CD45-CD49f+ cells in tumors 
from mice treated vehicle and paclitaxel for 24h and 5 days. (G) Representative 
histogram of PD-L1 surface expression in KBP cells treated with the indicated doses of 
paclitaxel for 24h. (H) Representative FACS plot of IL-10, IL-17 and IL-12 in 
CD11b+F4/80+ cells isolated from vehicle- and paclitaxel-treated tumors at 5 days post-
treatment. (I) Representative histogram of phospho-p65 levels in TAM (CD49flow/-CD45+ 
CD11b+ F4/80+ CD206+ PD-L1+) isolated from KBP tumors 5 days after treatment with 
paclitaxel or vehicle. n=6/group. (J) Positive correlation between M1 or M2 gene 
expression signatures (as determined by Chung et al, 2018 and Azizi et al., 2018) and 
the expression levels of PD-L1, p65/NFKB1 and the “Chuang oxidative stress response” 
gene signature in the TCGA human HR-defective BC cohort. See Materials and Methods 
for details. Data in C and D are presented as mean ± S.E.M of biological replicates. 
*P≤0.05, **P≤0.01, ***P≤0.001. 
Figure S5: Paclitaxel and PD-L1 blockade affects pathological features of KBP 
mammary tumors. (A) SRB cell viability assay in BMDM that were treated for 5 days 
with isotype control (10µg/ml) or paclitaxel (100nM)+aPD-L1 (10µg/ml).  (B, C) 
Percentage of CD206 (B) and MHC-II (C) positive cells within BMDM (CD49flow/-CD45+ 
CD11b+ F4/80+) treated as in (A) for 24h. (D) Pdl1 mRNA levels in BMDM treated as in 
(A). (E) Left, representative images of CD31-positive areas in tumors from mice treated 
with vehicle, isotype control, paclitaxel and aPD-L1 as indicated. Slides were 
counterstained with H&E. Right, quantification. n=5. (F) Representative images of P-p65 
positive cells in tumor tissues from mice treated as in (E). Slides were counterstained 
with H&E. (G) Representative images of cleaved caspase 3 immunostaining in tumors 
treated as in (E). Data in B-E are presented as mean ± S.E.M of biological replicates.  
Figure S6: Paclitaxel and PD-L1 blockade affects the immune profile of KBP 
mammary tumors. (A) Percentage of CD4+ T cells gated on live CD49f- CD45+ CD3+cells 
and isolated from KBP tumors at day 14 in mice treated with vehicle, isotype control 
paclitaxel and aPD-L1 as indicated. n=10-15/group. (B) Representative FACS plot of 
CD4+ and CD8+ population in tumors from mice treated as in (A). (C) Percentage of 
FoxP3+ cells gated on CD49f- CD45+ CD3+ CD4+ CD25+ cells and isolated from KBP 
tumors at day 14 in mice treated as in (A). n=10-15/group. (D) Percentage of CD8+ T cells 
gated on live CD49f- CD45+ CD3+cells isolated from KBP tumors at day 14 in mice treated 
as in (A). n=10-15/group. (E) Representative FACS plot of CD8+ population stained for 
CD44 and CD62L to define naïve, memory and effector T cell subpopulations in tumors 
from mice treated as in (A). (F-I) Representative FACS plots showing the levels of IFN-g, 
Granzyme-B, PD-1 and CD107a in CD8+ population in tumors from mice treated as in 
(A). Data in A, C and D are presented as mean ± S.E.M of biological replicates. *P≤0.05, 
**P≤0.01, ***P≤0.001. 
	
